Skip to content
Bomb Report – Lifestyle
Author:
Elicio Therapeutics Inc.
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
August 13, 2026
Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma
August 10, 2026
Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering
July 6, 2026
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
July 2, 2026
Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes
June 29, 2026
Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
June 17, 2026
Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer
June 15, 2026
Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company’s AMP-DNA Adjuvant Technology
June 1, 2026
Elicio Therapeutics to Present at the Bank of America Healthcare Conference
April 30, 2026
Elicio Therapeutics Reports Inducement Grants
April 16, 2026
1
2
Next Page
→